Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation

European Journal of Cardio-thoracic Surgery

Volumn 16, Issue 3, 1999, Pages 342-350

  Wendel, Hans Peter ^a   Ziemer, Gerhard ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b NONE

Author keywords

Extracorporeal circulation; Hemocompatibility; Heparin coating

Indexed keywords

CD11B ANTIGEN; CYTOKINE; ENDOTOXIN; FIBRIN; GLYCOPROTEIN P 15095; HEPARIN; NITRIC OXIDE; OXYGEN RADICAL; THROMBOCYTE ACTIVATING FACTOR;

BLEEDING; BLOOD COMPATIBILITY; BRAIN DISEASE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COST BENEFIT ANALYSIS; COST CONTROL; DEVICE; EXTRACORPOREAL CIRCULATION; HEART SURGERY; HEPARIN COATING; HOSPITALIZATION; HUMAN; LEUKOCYTE ACTIVATION; LUNG FUNCTION; MEDIATOR RELEASE; OXYGENATOR; PERFUSION; PRIORITY JOURNAL; REVIEW; SURFACE PROPERTY; SURGICAL DRAINAGE; TECHNIQUE; THROMBOCYTE; TREATMENT OUTCOME;

ANIMALS; ANTICOAGULANTS; BLOOD PHYSIOLOGY; COATED MATERIALS, BIOCOMPATIBLE; CORONARY DISEASE; EQUIPMENT DESIGN; EQUIPMENT SAFETY; EXTRACORPOREAL CIRCULATION; HEPARIN; HUMANS; MATERIALS TESTING; SENSITIVITY AND SPECIFICITY;

EID: 0033199710     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1010-7940(99)00210-9     Document Type: Review

References (91)

1. Market analysis: perfusion. In: Theta Reports, editor. Theta reports-cardiac equipment and materials markets. New York (212) 262-8230,1997:92-129.
2. Taylor K.M. SIRS - the systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg. 61:1996;1607-1608.
3. Müller E. Adult respiratory distress syndrome (ARDS): activation of complement, coagulation and fibrinolytic systems. Biomedical Progress. 4:1991;3-6.
4. Colman R.W. Hemostatic complications of cardiopulmonary bypass. Am J Hematol. 48:1995;267-272.
5. Bannan S., Martin P.G. Aprotinin complements heparin bonding in an in vitro model of cardiopulmonary bypass. Br J Haematol. 101:1998;455-461.
6. Baufreton C., Jansen P.G., Le Besnerais P., te Velthuis H., Thijs C.M., Wildevuur C.R., Loisance D.Y. Heparin coating with aprotinin reduces blood activation during coronary artery operations. Ann Thorac Surg. 63:1997;50-56.
7. Marcum J.A., Rosenberg R.D. The biochemistry, cell biology, and pathophysiology of anticoagulantly heparin-like molecules of the vessel wall. Lane D.A., Lindahl U., Heparin: clinical and biological properties, clinical applications. 1989;275-294 CRC Press, Boca Raton FL.
8. Gott V.L., Whiffen J.D., Dutton R.C. Heparin bonding on colloidal graphite surfaces. Science. 142:1963;1297-1298.
9. Larm O., Larsson R., Olsson P. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomater Med Devices Artif Organs. 11:1983;161-173.
10. Gravlee G.P. Heparin-coated cardiopulmonary bypass circuits. J Cardiothorac Vasc Anesth. 8:1994;213-222.
11. Janvier G., Baquey C., Roth C., Benillan N., Belisle S., Hardy J.F. Extracorporeal circulation, hemocompatibility, and biomaterials. Ann Thorac Surg. 62:1996;1926-1934.
12. Hsu L.C. Biocompatibility in cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 11:1997;376-382.
13. Wahba A., Philipp A., Behr R., Birnbaum D.E. Heparin-coated equipment reduces the risk of oxygenator failure. Ann Thorac Surg. 65:1998;1310-1312.
14. Von Segesser L.K., Weiss B.M., Pasic M., Garcia E., Turina M.I. Risk and benefit of low systemic heparinization during open heart operations. Ann Thorac Surg. 58:1994;391-397.
15. Borowiec J., Thelin S., Bagge L., van der Linden J., Thorno E., Hansson H.E. Heparin-coated cardiopulmonary bypass circuits and 25% reduction of heparin dose in coronary artery surgery - a clinical study. Ups J Med Sci. 97:1992;55-66.
16. Kuitunen A.H., Heikkila L.J., Salmenpera M.T. Cardiopulmonary bypass with heparin-coated circuits and reduced systemic anticoagulation. Ann Thorac Surg. 63:1997;438-444.
17. Aldea G.S., Zhang X., Memmolo C.A., Shapira O.M., Treanor P.R., Kupferschmid J.P., Lazar H.L., Shemin R.J. Enhanced blood conservation in primary coronary artery bypass surgery using heparin-bonded circuits with lower anticoagulation. J Card Surg. 11:1996;85-95.
18. Ovrum E., Brosstad F., Am Holen E., Tangen G., Abdelnoor M. Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass. Circulation. 92:1995;2579-2584.
19. Pekna M., Borowiec J.W., Fagerhol M.K., Venge P., Thelin S. Biocompatibility of heparin-coated circuits used in cardiopulmonary bypass. Scand J Thorac Cardiovasc Surg. 28:1994;5-11.
20. Ovrum E., Mollnes T.E., Fosse E., Holen E.A., Tangen G., Ringdal M.A., Videm V. High and low heparin dose with heparin-coated cardiopulmonary bypass: activation of complement and granulocytes. Ann Thorac Surg. 60:1995;1755-1761.
21. Von Segesser L.K., Weiss B.M., Garcia E., von Felten A., Turina M.I. Reduction and elimination of systemic heparinization during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 103:1992;790-799.
22. Aldea G.S., O'Gara P., Shapira O.M., Treanor P., Osman A., Patalis E., Arkin C., Diamond R., Babikian V., Lazar H.L., Shemin R.J. Effect of anticoagulation protocol on outcome in patients undergoing CABG with heparin-bonded cardiopulmonary bypass circuits. Ann Thorac Surg. 65:1998;425-433.
23. Aldea G.S., Doursounian M., O'Gara P., Treanor P., Shapira O.M., Lazar H.L., Shemin R.J. Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: a prospective, randomized study. Ann Thorac Surg. 62:1996;410-417.
24. Borowiec J., Thelin S., Bagge L., Hultman J., Hansson H.E. Decreased blood loss after cardiopulmonary bypass using heparin-coated circuit and 50% reduction of heparin dose. Scand J Thorac Cardiovasc Surg. 26:1992;177-185.
25. Bannan S., Danby A., Cowan D., Ashraf S., Martin P.G. Low heparinization with heparin-bonded bypass circuits: is it a safe strategy? Ann Thorac Surg. 63:1997;663-668.
26. Mahoney C.B. Heparin-bonded circuits: clinical outcomes and costs. Perfusion. 13:1988;192-204.
27. Boisclair M.D., Lane D.A., Philippou H., Esnouf M.P., Sheikh S., Hunt B., Smith K.J. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood. 82:1993;3350-3357.
28. Vroman L. The life of an artificial device in contact with blood: initial events and their effect on its final state. Bull NY Acad Med. 64:1998;352-357.
29. Moen O., Hogasen K., Fosse E., Dregelid E., Brockmeier V., Venge P., Harboe M., Mollnes T.E. Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg. 63:1997;105-111.
30. Wan S., LeClerc J.L., Vincent J.L. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest. 112:1997;676-692.
31. Didisheim D., Watson J. Thromboembolic complications of cardiovascular devices and artificial surfaces. Kwaan H., Samama M.Y., Clinical thrombosis. 1989;275-296 CRC Press, Boca Raton.
32. Fuhrer G., Gallimore M.J., Heller W., Hoffmeister H.E. F XII (Review). Blut. 61:1990;258-266.
33. Colman R.W., Scott C.F., Schmaier A.H., Wachtfogel Y.T., Pixley R.A., Edmunds Jr L.H. Initiation of blood coagulation at artificial surfaces. Leonard E.F., Turrito V.T., Vroman L., Ann NY Acad Sci. 1987;253-267.
34. Mammen E.F. Contact activation: the interaction of clotting, fibrinolytic, kinin and complement systems. Biomedical Progress. 2:1990;31-34.
35. Jansen P.G., te Velthuis H., Huybregts R.A., Paulus R., Bulder E.R., van der Spoel H.I., Bezemer P.D., Slaats E.H., Eijsman L., Wildevuur C.R.H. Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits. J Thorac Cardiovasc Surg. 110:1995;829-834.
36. Elgue G., Blomback M., Olsson P., Riesenfeld J. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin. Thromb Haemost. 70:1993;289-293.
37. Moen O., Fosse E., Dregelid E., Brockmeier V., Andersson C., Hogasen K., Venge P., Mollnes T.E., Kierulf P. Centrifugal pump and heparin coating improves cardiopulmonary bypass biocompatibility. Ann Thorac Surg. 62:1996;1134-1140.
38. Korn R.L., Fisher C.A., Livingston E.R., Stenach N., Fishman S.J., Jeevanadam V., Addonizio V.P. The effects of Carmeda Bioactive Surface on human blood components during simulated extracorporeal circulation. J Thorac Cardiovasc Surg. 111:1996;1073-1084.
39. Wagner W.R., Johnson P.C., Thompson K.A., Marrone G.C. Heparin-coated cardiopulmonary bypass circuits: hemostatic alterations and postoperative blood loss. Ann Thorac Surg. 58:1994;734-740.
40. Fukutomi M., Kobayashi S., Niwaya K., Hamada Y., Kitamura S. Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment. Artif Organs. 20:1996;767-776.
41. Kagisaki K., Masai T., Kadoba K., Sawa Y., Nomura F., Fukushima N., Ichikawa H., Ohata T., Suzuki K., Taketani S., Matsuda H. Biocompatibility of heparin-coated circuits in pediatric cardiopulmonary bypass. Artif Organs. 21:1997;836-840.
42. Ovrum E., Fosse E., Mollnes T.E., Am Holen E., Tangen G., Abdelnoor M., Ringdal M.A., Oystese R., Venge P. Complete heparin-coated cardiopulmonary bypass and low heparin dose reduce complement and granulocyte activation. Eur J Cardiothorac Surg. 10:1996;54-60.
43. Ovrum E., Mollnes T.E., Fosse E., Holen E.A., Tangen G., Abdelnoor M., Ringdal M.A., Oystese R., Venge P. Complement and granulocyte activation in two different types of heparinized extracorporeal circuits. J Thorac Cardiovasc Surg. 110:1995;1623-1632.
44. Svenmarker S., Sandström E., Karlsson T., Jansson E., Häggmark S., Lindholm R., Appelblad M., Aberg T. Clinical effects of the heparin coated surface in cardiopulmonary bypass. Eur J Cardiothorac Surg. 11:1997;957-964.
45. Bozdayi M., Borowiec J., Nilsson L., Venge P., Thelin S., Hansson H.E. Effects of heparin coating of cardiopulmonary bypass circuits on in vitro oxygen free radical production during coronary bypass surgery. Artif Organs. 20:1996;1008-1016.
46. Hogevold H.E., Moen O., Fosse E., Venge P., Braten J., Andersson C. Effects of heparin coating on the expression of CD11b. CD11c and CD62L by leucocytes in extracorporeal circulation in vitro. Perfusion. 12:1997;9-20.
47. Moen O., Fosse E., Brockmeier V., Andersson C., Mollnes T.E., Hogasen K., Venge P. Disparity in blood activation by two different heparin-coated cardiopulmonary bypass systems. Ann Thorac Surg. 60:1995;1317-1323.
48. Lundblad R., Moen O., Fosse E. Endothelin-1 and neutrophil activation during heparin-coated cardiopulmonary bypass. Ann Thorac Surg. 63:1997;1361-1367.
49. Baba T., Morisita K., Sakata J., Ito T., Hachiro Y., Kazui T., Abe A., Komatu S. Experimental studies on three types of heparin-coated cardiopulmonary circuits. Artificial Organs. 21:(7):1997;779-781.
50. Akihiko U., Fumihiko M., Hideki O., Yasuhiro T., Katsuhiko Y., Michiaki H., Mitsuo K., Mitsuya M. A clinical study for the durability of oxygenators on cardiopulmonary support. Artificial Organs. 21:(7):1997;772-778.
51. Palatianos G.M., Dewanjee M.K., Smith W., Novak S., Hsu L.C., Kapadvanjwala M., Sfakianakis G.N., Kaiser G.A. Platelet preservation during cardiopulmonary bypass with iloprost and Duraflo-II heparin-coated surfaces. ASAIO Trans. 37:1991;620-622.
52. Horimoto H., Kondo K., Asada K., Sasaki S. Heparin-coated cardiopulmonary bypass circuits in coronary bypass surgery. Artif Organs. 20:1996;936-940.
53. te Velthuis H., Jansen P.G., Hack C.E., Eijsman L., Wildevuur C.R.H. Specific complement inhibition with heparin-coated extracorporeal circuits. Ann Thorac Surg. 61:1996;1153-1157.
54. Yamanaka J., Takeuchi Y., Torii S., Gomi A., Nakatani H., Kohno K. The evaluation of the bio-compatibility and the clinical usefulness of heparin-coated cardiopulmonary bypass circuits. Nippon Kyobu Geka Gakkai Zasshi. 44:1996;47-53.
55. Ranucci M., Cirri S., Conti D., Ditta A., Boncilli A., Frigiola A., Menicanti L. Beneficial effects of Duraflo II heparin-coated circuits on postperfusion lung dysfunction. Ann Thorac Surg. 61:1996;76-81.
56. Wildevuur C.R.H., Jansen P.G., Bezemer P.D., Kuik D.J., Eijsman L., Bruins P., de Jong D., Van Hardevelt F.W.J., Biervliet J.D., Hasenkam J.M., Kure H.H., Knudsen L., Bellaiche L., Ahlburg P., Loisance D.Y., Baufreton C., Le Besnerais P., Bajan G., Matta A., Van Dyck M., Renotte M.T., Ponlot-Lois A., Baele P.L., Mcgovern E.A., McCarthy J., McCarthy A., O'Donell A., Fosse E., Moen O., Dregelid E., Brockmeier V., Anderson C., Pomar J.L., Ranucci M., Conti D., Cirri S., Conti E., Ditta A., Von Segesser L.K., Tkebuchava T., Weiss B.M., Turina M.I., Svennevig J.L., Mohr B., Videm V., Karlsen H., Pedersen T.H., Thelin S., Halden E., Hagman L., Thörnö E., Ahlvin E. Clinical evaluation of Duraflo II heparin treated extracorporeal circulation circuits (2nd version). The European working group on heparin coated extracorporeal circulation circuits. Eur J Cardiothorac Surg. 11:1997;616-623.
57. Wendel H.P., Klaffschenkel R., Heller W., Hoffmeister H.E. Kardiopulmonaler Bypass unter Verzicht von Antikoagulantien? - Ex-vivo-Modelluntersuchungen mit Verwendung eines heparinbeschichteten Membranoxygenators. Fraedrich G., von Segesser L.K., Hasse J., Schlosser V., Besondere aspekte der extrakorporalen zirkulation. 1992;47-52 Steinkopff Verlag, Darmstad.
58. Tkebuchava T., Von Segesser L.K., Leskosek B., Pei P., Turina M. Thrombosis-resistant heparin-coated diffusion membrane oxygenators: an experimental study. Swiss Surg Suppl. 1:1996;36-40.
59. van der Kamp K.W., Magielse C.P., Elstrodt J.M., van der Meer J., van Oeveren W., Rakhorst G. Blood interaction with a Bioline heparin coated HIA-VAD: a study on calves. Int J Artif Organs. 20:1997;43-50.
60. Fraedrich G., Hoh A., Scheidel U., Mayer U.H., Böhler J., Beyersdorf F. A new covalent heparin bonding process of extracorporeal circuits improves the hemocompatibility of cardiopulmonary bypass (Abstract 112). CREF. San Diego 1995.
61. Knobl H.J., Kind K., Dramburg W., Weigkemper H.H., Breymann T., Thies W.R., Brinkmann T., Körfer R. Erste klinische Erfahrungen mit der Bioline Coating-Beschichtung bei Säuglingen und Kleinkindern mit kongenitalen Vitien - Beschichtung des extracorporalen Systems (Abstract). Int T Ges Kardiotech. 1995;24.
62. Matheis G., Wimmer-Greinecker G., Beholz S., Skupin M., Baum R.P., Meisel M., Oremek G., Beyersdorf F., Moritz A. Heparin-coated cardiopulmonary bypass is associated with reduced pulmonary and cerebral injury (Abstract 185). Thorac Cardiovasc Surg. 1996;44.
63. Larsson R., Larm O., Olsson P. The search for thromboresistance using immobilized heparin. Ann NY Acad Sci. 516:1987;102-107.
64. Zwaal R.F.A., Comfurius P., van Deenen L.L.M. Membrane assymmetry and blood coagulation. Nature. 268:1977;358-360.
65. Chapman D., Lee D.C. Dynamics and structure of biomembranes. Biochem Soc Trans. 15:1987;475-545.
66. Yianni Y.P. Biocompatible surfaces based upon biomembrane mimicry. Quinn P.J., Cherry R.J., Structural and Dynamic Properties of Lipids and Membranes. 1992;187-216 Portland Press Ltd, London.
67. Von Segesser L.K., Tonz M., Leskosek B., Turina M. Evaluation of phospholipidic surface coatings ex-vivo. Int J Artif Organs. 17:1994;294.
68. Campbell E.J., O'Byrne V., Stratford P.W., Quirk I., Vick T.A., Wiles M.C., Yianni Y.P. Biocompatible surfaces using methacryloylphosphorylcholine laurylmethacrylate copolymer. ASAIO J. 40:1994;853-857.
69. Tsai C.C., Deppisch R.M., Forrestal L.J., Ritzau G.H., Oram A.D., Göhl H.J., Voorhees M.E. Surface modifying additives for improved device-blood compatibility. ASAIO J. 40:1994;M619-M624.
70. Gu Y.J., Boonstra P.W., Rijnsburger A.A., Haan J., van Oeveren W. Cardiopulmonary bypass circuit treated with surface-modifying additives: a clinical evaluation of blood compatibility. Ann Thorac Surg. 65:1998;1342-1347.
71. Von Segesser L.K., Gyurech D.D., Schilling J.J., Marquardt K., Turina M.I. Can protamine be used during perfusion with heparin surface coated equipment? ASAIO J. 39:1993;M190-M194.
72. Muehrcke D.D., McCarthy P.M., Stewart R.W., Seshagiri S., Ogella D.A., Foster R.C., Cosgrove D.M. Complications of extracorporeal life support systems using heparin-bound surfaces. The risk of intracardiac clot formation. J Thorac Cardiovasc Surg. 110:1995;843-851.
73. Hendrikx M., Leunens V., Vandezande E., Wallyn A., Flameng W. The use of a heparin removal device: a valid alternative to protamine. Int J Artif Organs. 20:1997;166-174.
74. Belboul A., Al-Khaja N. Does heparin coating improve biocompatibility? A study on complement, blood cells and postoperative morbidity during cardiac surgery. Perfusion. 12:1997;385-391.
75. Borowiec J., Bagge L., Saldeen T., Thelin S. Biocompatibility reflected by haemostasis variables during cardiopulmonary bypass using heparin-coated circuits. Thorac Cardiovasc Surg. 45:1997;163-167.
76. Gorman R.C., Ziats N., Rao A.K., Gikakis N., Sun L., Khan M.M., Stenach N., Sapatnekar S., Chouhan V., Gorman J.H. 3rd., Niewiarowski S., Colman R.W., Anderson J.M., Edmunds L.H. Jr. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg. 111:1996;1-11.
77. Borowiec J.W., Hagman L., Totterman T.H., Pekna M., Venge P., Thelin S. Circulating cytokines and granulocyte-derived enzymes during complex heart surgery. A clinical study with special reference to heparin-coating of cardiopulmonary bypass circuits. Scand J Thorac Cardiovasc Surg 1995. 29:1995;167-174.
78. Steinberg B.M., Grossi E.A., Schwartz D.S., McLoughlin D.E., Aguinaga M., Bizekis C., Greenwald J., Flisser A., Spencer F.C., Colvin S.B., Galloway A.C. Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass. Ann Thorac Surg. 60:1995;525-529.
79. Weiss B.M., Von Segesser L.K., Turina M.I., Seifert B., Pasch T. Perioperative course and recovery after heparin-coated cardiopulmonary bypass: low-dose versus high-dose heparin management. J Cardiothorac Vasc Anesth. 10:1996;464-470.
80. Ovrum E., Brosstad F., Am Holen E., Tangen G., Abdelnoor M., Oystese R. Complete heparin-coated (CBAS) cardiopulmonary bypass and reduced systemic heparin dose; effects on coagulation and fibrinolysis. Eur J Cardiothorac Surg. 10:1996;449-455.
81. Ernofsson M., Thelin S., Siegbahn A. Thrombin generation during cardiopulmonary bypass using heparin-coated or standard circuits. Scand J Thorac Cardiovasc Surg. 29:1995;157-165.
82. Spiess B.D., Vocelka C., Cochran R.P., Soltow L., Chandler W.L. Heparin-coated bypass circuits (Carmeda) suppress the release of tissue plasminogen activator during normothermic coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 12:1998;299-304.
83. Saenz A., Larranaga G., Alvarez L., Greco E., Marrero A., Lunar M., Elosegui C., Ubago J.L., Gallo I. Heparin-coated circuit in coronary surgery. A clinical study. Eur J Cardiothorac Surg. 10:1996;48-53.
84. Yamada H., Kudoh I., Hirose Y., Toyoshima M., Abe H., Kurahashi K. Heparin-coated circuits reduce the formation of TNF alpha during cardiopulmonary bypass. Acta Anaesthesiol Scand. 40:1996;311-317.
85. Fosse E., Thelin S., Svennevig J.L., Jansen P., Mollnes T.E., Hack E., Venge P., Moen O., Brockmeier V., Dregelid E., Halden E., Hagman L., Videm V., Pedersen T., Mohr B. Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes: a European multicentre study. Eur J Cardiothorac Surg. 11:1997;320-327.
86. Ernofsson M., Thelin S., Siegbahn A. Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass: a clinical study. J Thorac Cardiovasc Surg. 113:1997;576-584.
87. Hamulu A., Discigil B., Ozbaran M., Calkavur T., Kara E., Kokuludag A., Buket S., Bilkay O. Complement consumption during cardiopulmonary bypass: comparison of Duraflo II heparin-coated and uncoated circuits in fully heparinized patients. Perfusion. 11:1996;333-337.
88. te Velthuis H., Baufreton C., Jansen P.G., Thijs C.M., Hack C.E., Sturk A., Wildevuur C.R., Loisance D.Y. Heparin coating of extracorporeal circuits inhibits contact activation during cardiac operations. J Thorac Cardiovasc Surg. 114:1997;117-122.
89. Barstad R.M., Ovrum E., Ringdal M.A., Oystese R., Hamers M.J., Veiby O.P., Rolfsen T., Stephens R.W., Sakariassen K.S. Induction of monocyte tissue factor procoagulant activity during coronary artery bypass surgery is reduced with heparin-coated extracorporeal circuit. Br J Haematol. 94:1996;517-525.
90. Muehrcke D.D., McCarthy P.M., Kottke Merchant K., Harasaki H., Pierre Yared J., Borsh J.A., Ogella D.A., Cosgrove D.M. Biocompatibility of heparin-coated extracorporeal bypass circuits: a randomized, masked clinical trial. J Thorac Cardiovasc Surg. 112:1996;472-483.
91. Ovrum E., Holen E.A., Tangen G., Brosstad F., Abdelnoor M., Ringdal M.A., Oystese R., Istad R. Completely heparinized cardiopulmonary bypass and reduced systemic heparin: clinical and hemostatic effects. Ann Thorac Surg. 60:1995;365-371.